CSIS Health Corp

CSIS Health Corp develops technology that addresses the $200 billion per annum cost caused by unnecessary medication use. Our current medication review solution focuses on preventing harmful and inappropriate prescribing in patients with multiple chronic conditions, which can lead to Adverse Drug Events (ADEs) and hospitalization. As a patient-centred medication review solution, its applies both the AGS Beers Criteria® and StoppStart® Criteria to patient electronic medical records. The AGS Beers Criteria® and StoppStart® Criteria are international best practice prescribing rules for patients with multiple conditions and polypharmacy. CSIS Health Corp is the only company licenced to apply AGS Beers Criteria® and StoppStart® Criteria. We have an exclusive commercial partnership with the American Geriatrics Society (AGS) to deliver the first electronic version of the AGS Beers Criteria® through our medication review solution.